Will last year's buybacks morph into more M&A for 2012?

After spending last year focusing on billion-dollar share buybacks to shore up their stock and please investors, European pharma companies may focus more on dealmaking this year, analysts say. Report

Suggested Articles

Merck's Keytruda has new long-term survival results that the drugmaker hopes will help bolster its position in first-line NSCLC.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.